- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02170909
Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin
August 29, 2018 updated by: Boehringer Ingelheim
Safety, Pharmacokinetics and Pharmacodynamics After Single (150 mg, 220 mg and 300 mg) and Multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) Rising Oral Doses of BIBR 1048 MS/Capsules in Healthy Male Subjects of Japanese and Caucasian Origin. (Open Label Study)
Study to investigate and compare safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of single (150 mg, 220 mg and 300 mg) and multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) rising doses in healthy male subjects of Japanese and Caucasian origin.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Healthy male subjects of Japanese or Caucasian origin according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, respiratory rate and tympanic body temperature), 12- lead ECG (electrocardiogram), clinical laboratory tests
- 1.1 No finding deviating from normal and of clinical relevance
- 1.2 No evidence of a clinically relevant concomitant disease
- Age ≥ 20 and Age ≤ 45 years
- Body mass index (BMI) ≥ 18 and ≤ 25 kg/m2
- Japanese subjects were from a well-defined Japanese population, both parents of Japanese origin and the subjects have Japanese passport and had lived ≤ 8 years outside Japan.
- Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation.
Exclusion Criteria:
- Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women, or an unwillingness of male subjects to use an adequate form of contraception as well as having their female partner(s) use another form of contraception (if the woman possibly become pregnant) from the time of the single dose on Day 1 until Day 22-26 (end-of study examination)
- Current diseases of the central nervous system (such as epilepsy), or psychiatric disorders or neurological disorders
- History of clinically significant orthostatic hypotension, clinically significant current or past fainting spells or blackouts
- Chronic or relevant acute infections
History of
- allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- any bleeding disorder including prolonged or habitual bleeding
- other hematologic disease
- cerebral bleeding (e.g. after a car accident)
- concussions (head trauma resulting in injuring to brain) with or without loss of consciousness
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives, whichever is shorter, of the respective drug prior to administration or during the trial
- Use of acetylsalicylic acid (ASA)-containing over-the-counter medications, clopidogrel or ticlopidine or dipyridamole, chronic administration of non-steroidal anti-inflammatory drugs (NSAIDs) (cyclooxygenase-2 (COX-2) inhibitors excluded), coumadin like anticoagulants, chronic use of corticosteroids, heparin and fibrinolytic agents within 14 days prior to administration or during the trial.
- Participation in another trial with an investigational drug within three months prior to administration or during the trial
- Smoker (> 10 cigarettes/day or > 3 cigars/day or > 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (more than 21unit/week; one unit was approximately half a pint of beer, a small glass of wine or one measure of spirits)
- History of drug abuse
- Blood donation (more than 100 mL within three months prior to screening administration and any blood donation from screening to end-of-study examination)
- Excessive physical activities (within one week prior to administration or during the trial and until end-of-study examination)
- Any laboratory value outside the reference range that was of clinical relevance
- Inability to comply with dietary regimen of study centre
- Known hypersensitivity to the drug or its excipients
- History of any familial bleeding disorder
- Thrombocytes < 150000/μL
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BIBR 1048 MS low dose
|
|
Experimental: BIBR 1048 MS medium dose
|
|
Experimental: BIBR 1048 MS high dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in vital signs
Time Frame: Baseline and up to day 26
|
Baseline and up to day 26
|
Change in 12-lead electrocardiogram (ECG)
Time Frame: Baseline and up to day 26
|
Baseline and up to day 26
|
Change in clinical laboratory tests
Time Frame: Baseline and up to day 26
|
Baseline and up to day 26
|
Occurence of adverse events
Time Frame: Up to day 26
|
Up to day 26
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the curve (AUC) from 0-24 hours for activated partial thromboplastin time (aPTT)
Time Frame: Day 1 and 12
|
Day 1 and 12
|
AUC from 0-24 hours for ecarin clotting time (ECT)
Time Frame: Day 1 and 12
|
Day 1 and 12
|
Change in thrombin time (TT)
Time Frame: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Change in prothrombin time (PT) expressed as international normalised ratio (INR)
Time Frame: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Maximum value of aPTT
Time Frame: Up to 72 hours after administration on day 1 and 12
|
Up to 72 hours after administration on day 1 and 12
|
Maximum value of ECT
Time Frame: Up to 72 hours after administration on day 1 and 12
|
Up to 72 hours after administration on day 1 and 12
|
Change in ECT
Time Frame: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Change in aPTT
Time Frame: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Cmax (maximum measured concentration of the analyte in plasma)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
tmax (time from dosing to maximum measured concentration of the analyte in plasma)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the single dose on day 1)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
λz (terminal rate constant in plasma)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
t1/2 (terminal half-life of the analyte in plasma)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
MRTpo (mean residence time of the analyte in the body after po administration)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
CL/F (apparent clearance of the analyte in plasma following extravascular administration)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular administration)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Time Frame: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
λz,ss (terminal rate constant in plasma at steady state)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
t1/2,ss (terminal half-life of the analyte in plasma at steady state)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
MRTpo,ss (mean residence time of the analyte in the body at steady state after po administration)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Aet1-t2,ss (amount of analyte that is eliminated in urine at steady state from the time point t1 to time point t2)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
fet1-t2,ss (fraction of analyte eliminated in urine at steady state from time point t1 to time point t2)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
CLR,t1-t2,ss (renal clearance of the analyte in plasma from the time point t1 until the time point t2 at steady state)
Time Frame: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Accumulation ratio RA,Cmax,7 based on Cmax
Time Frame: Day 6 to day 15
|
Day 6 to day 15
|
Accumulation ratio RA,AUC,7 based on AUCτ (only for 150 mg and 220 mg q.d. groups)
Time Frame: Day 6 to day 15
|
Day 6 to day 15
|
Linearity index (LI) based on AUC (only for 150 mg and 220 mg q.d. groups)
Time Frame: Day 6 to day 15
|
Day 6 to day 15
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2004
Primary Completion (Actual)
June 1, 2005
Study Registration Dates
First Submitted
June 20, 2014
First Submitted That Met QC Criteria
June 20, 2014
First Posted (Estimate)
June 23, 2014
Study Record Updates
Last Update Posted (Actual)
August 31, 2018
Last Update Submitted That Met QC Criteria
August 29, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1160.29
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on BIBR 1048 MS low dose
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted